{"id":"rifamycin-containing-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Drug interactions (enzyme induction)"},{"rate":null,"effect":"Orange discoloration of body fluids"}]},"_chembl":{"chemblId":"CHEMBL236921","moleculeType":"Small molecule","molecularWeight":"695.76"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifamycins are a class of antibiotics that bind to the bacterial RNA polymerase enzyme and inhibit RNA synthesis by blocking the path of elongating RNA transcripts. This mechanism is highly selective for bacterial RNA polymerase and has minimal effect on eukaryotic enzymes. Rifamycin-containing regimens are typically used in combination with other antimicrobial agents to treat infections caused by susceptible bacteria, particularly Mycobacterium tuberculosis and other mycobacterial species.","oneSentence":"Rifamycins inhibit bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:04.963Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (as part of combination therapy)"},{"name":"Mycobacterial infections"},{"name":"Other bacterial infections (in combination regimens)"}]},"trialDetails":[{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT04311502","phase":"PHASE2","title":"Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-05","conditions":"HIV, Tuberculosis","enrollment":104},{"nctId":"NCT06917495","phase":"PHASE2","title":"Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2025-04-05","conditions":"Mild Spinal Tuberculosis","enrollment":300},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT05502913","phase":"PHASE2","title":"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer","status":"RECRUITING","sponsor":"Soroka University Medical Center","startDate":"2023-09-01","conditions":"Metastatic Lung Cancer","enrollment":80},{"nctId":"NCT02256696","phase":"PHASE2","title":"Assessing PA-824 for Tuberculosis (the APT Trial)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-04-29","conditions":"Pulmonary Tuberculosis","enrollment":157},{"nctId":"NCT05588492","phase":"PHASE4","title":"The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-01-01","conditions":"Pulmonology","enrollment":500},{"nctId":"NCT05454345","phase":"PHASE3","title":"Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-10-01","conditions":"Tuberculosis, Pulmonary","enrollment":620},{"nctId":"NCT04501380","phase":"PHASE2","title":"Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)","status":"UNKNOWN","sponsor":"Bradley Connor","startDate":"2020-06-30","conditions":"Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease, Gastrointestinal Infection","enrollment":30},{"nctId":"NCT00001058","phase":"PHASE2","title":"A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":246},{"nctId":"NCT00598897","phase":"PHASE4","title":"Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1995-08","conditions":"Mycobacterium Avium Complex Lung Disease","enrollment":89},{"nctId":"NCT00598962","phase":"PHASE4","title":"Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1994-12","conditions":"Mycobacterium Avium Complex","enrollment":58},{"nctId":"NCT00864383","phase":"PHASE3","title":"Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2008-01","conditions":"Pulmonary Tuberculosis","enrollment":1931},{"nctId":"NCT00694629","phase":"PHASE2","title":"TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2008-12","conditions":"Pulmonary Tuberculosis","enrollment":865},{"nctId":"NCT01259219","phase":"PHASE1","title":"Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra","status":"UNKNOWN","sponsor":"Harriet Shezi Children's Clinic","startDate":"2010-11","conditions":"Children With Confirmed HIV Infection, Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose, Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment","enrollment":40},{"nctId":"NCT00002101","phase":"PHASE3","title":"A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo","status":"COMPLETED","sponsor":"Pharmacia","startDate":"","conditions":"Mycobacterium Avium-Intracellulare Infection, HIV Infections","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rifamycin-containing regimen","genericName":"Rifamycin-containing regimen","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifamycins inhibit bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis. Used for Tuberculosis (as part of combination therapy), Mycobacterial infections, Other bacterial infections (in combination regimens).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}